Relieves symptoms of depression. ANDA 90441, held by Chartwell. Imipramine Hydrochloride.
As of Nov 16, 2026, ANDA 90441 (Imipramine Hydrochloride), held by Chartwell, was first approved by FDA on Mar 11, 2010, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Depression For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. Childhood Enuresis May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2010 | Original application | Approved | None posted |
| Imipramine Hydrochloride50MG · tablet;oral | Imipramine Hydrochloride | Discontinued |
| Imipramine Hydrochloride10MG · tablet;oral | Imipramine Hydrochloride | Discontinued |
| Imipramine Hydrochloride25MG · tablet;oral | Imipramine Hydrochloride | Discontinued |
| Jun 24, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 2, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 11, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters